93 related articles for article (PubMed ID: 11156123)
1. SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery.
Defraigne JO; Pincemail J; Dekoster G; Larbuisson R; Dujardin M; Blaffart F; David JL; Limet R
Ann Thorac Surg; 2000 Dec; 70(6):2075-81. PubMed ID: 11156123
[TBL] [Abstract][Full Text] [Related]
2. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility.
Gu YJ; Boonstra PW; Rijnsburger AA; Haan J; van Oeveren W
Ann Thorac Surg; 1998 May; 65(5):1342-7. PubMed ID: 9594864
[TBL] [Abstract][Full Text] [Related]
3. Cardiopulmonary bypass copolymer surface modification reduces neither blood loss nor transfusions in coronary artery surgery.
Südkamp M; Mehlhorn U; Reza Raji M; Hekmat K; Easo J; Geissler HJ; Sindhu D; de Vivie R
Thorac Cardiovasc Surg; 2002 Feb; 50(1):5-10. PubMed ID: 11847596
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass.
Ask A; Holt D; Smith L
J Extra Corpor Technol; 2006 Mar; 38(1):27-32. PubMed ID: 16637520
[TBL] [Abstract][Full Text] [Related]
5. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation.
Fromes Y; Gaillard D; Ponzio O; Chauffert M; Gerhardt MF; Deleuze P; Bical OM
Eur J Cardiothorac Surg; 2002 Oct; 22(4):527-33. PubMed ID: 12297167
[TBL] [Abstract][Full Text] [Related]
6. Do surface modifying additives (SMA) influence blood loss and thrombogenicity in conventional cardiopulmonary bypass for coronary artery bypass grafting?
Martens S; Matheis G; Wimmer-Greinecker G; Scherer M; Doss M; Moritz A
Cardiovasc Surg; 2003 Apr; 11(2):159-63. PubMed ID: 12664053
[TBL] [Abstract][Full Text] [Related]
7. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface.
De Somer F; François K; van Oeveren W; Poelaert J; De Wolf D; Ebels T; Van Nooten G
Eur J Cardiothorac Surg; 2000 Nov; 18(5):602-6. PubMed ID: 11053824
[TBL] [Abstract][Full Text] [Related]
10. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
[TBL] [Abstract][Full Text] [Related]
11. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer.
Rubens FD; Labow RS; Lavallée GR; Watson MI; Robblee JA; Voorhees ME; Nathan HJ
Ann Thorac Surg; 1999 Mar; 67(3):689-96; discussion 696-8. PubMed ID: 10215212
[TBL] [Abstract][Full Text] [Related]
12. Failure of surface-modified bypass circuits to improve platelet function during pediatric cardiac surgery.
Kirshbom PM; Miller BE; Spitzer K; Easley KA; Spainhour CE; Kogon BE; Kanter KR
J Thorac Cardiovasc Surg; 2006 Sep; 132(3):675-80. PubMed ID: 16935126
[TBL] [Abstract][Full Text] [Related]
13. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss.
Wagner WR; Johnson PC; Thompson KA; Marrone GC
Ann Thorac Surg; 1994 Sep; 58(3):734-40; discussion 741. PubMed ID: 7944696
[TBL] [Abstract][Full Text] [Related]
14. Coronary artery bypass grafting with a minimized cardiopulmonary bypass circuit: a prospective, randomized trial.
Sakwa MP; Emery RW; Shannon FL; Altshuler JM; Mitchell D; Zwada D; Holter AR
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):481-5. PubMed ID: 19185173
[TBL] [Abstract][Full Text] [Related]
15. A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass.
Misoph M; Babin-Ebell J; Schwender S
Thorac Cardiovasc Surg; 1997 Dec; 45(6):302-6. PubMed ID: 9477463
[TBL] [Abstract][Full Text] [Related]
16. Effect of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function.
Speziale G; Ferroni P; Ruvolo G; Fattouch K; Pulcinelli FM; Lenti L; Gazzaniga PP; Marino B
J Cardiovasc Surg (Torino); 2000 Dec; 41(6):819-27. PubMed ID: 11232964
[TBL] [Abstract][Full Text] [Related]
17. [Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass].
Ji HW; Chen L
Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(3):175-8. PubMed ID: 19537033
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: a prospective randomized trial.
Schulze CJ; Han L; Ghorpade N; Etches WS; Stang L; Koshal A; Wang SH
J Card Surg; 2009; 24(4):363-8. PubMed ID: 19583605
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
20. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass.
Rubens FD; Nathan H; Labow R; Williams KS; Wozny D; Karsh J; Ruel M; Mesana T
Ann Thorac Surg; 2005 Feb; 79(2):655-65. PubMed ID: 15680854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
